RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase not stated

Registered title, quoted from ClinicalTrials.gov

A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Peking University First Hospital; 2 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 3

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorPeking University First Hospital北京大学第一医院BeijingHospital page
  2. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  3. Study sitePeking University Third Hospital北京大学第三医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06436677, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Received other anti-tumor therapy other than skin-targeted therapy (phototherapy, topical hormones or nitrogen mustard) within the past 1 month prior to enrollment;

    Exclusion criterion 1

  3. Patients with renal insufficiency and creatinine clearance \< 50ml/min;

    Exclusion criterion 8

  4. Pregnant (or intending to become pregnant within 2 years) or lactating females;

    Exclusion criterion 15

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06436677, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Signed informed consent;
  • Patients with CTCL who do not respond well to targeted skin therapy (topical corticosteroids, nitrogen mustard, or phototherapy) in the early stage (stage I-IIA) and advanced stage (stage IIB-IV);
  • Age 18-75 years;
  • Expected survival time greater than 3 months (follow-up for the historical control group was greater than 3 months);

Exclusion Criteria:

  • Received other anti-tumor therapy other than skin-targeted therapy (phototherapy, topical hormones or nitrogen mustard) within the past 1 month prior to enrollment;
  • Patients with 2 or more types of primary cutaneous T-cell lymphoma at the same time;
  • Combined with other malignant tumors, still receiving anti-tumor therapy;
  • Has any other active disease that may increase the risk of protocol therapy or impair the patient\'s ability to receive protocol therapy, including but not limited to:
  • Comorbid epilepsy;
  • Comorbid autoimmune diseases;
  • Combined with hepatic decompensation;
  • Patients with renal insufficiency and creatinine clearance \< 50ml/min;
  • Have an uncontrollable medical condition, including but not limited to:
  • Ongoing or active infection;
  • Clinically significant healing or non-healing wounds;
  • Symptomatic congestive heart failure, unstable angina, clinically significant arrhythmias;
  • Significant lung disease (e.g., shortness of breath at rest or light activity, or need for supplemental oxygen for any reason);
  • Diseases/conditions that affect study compliance, such as infectious diseases or psychiatric illnesses/social situations, that are uncontrollable;
  • Pregnant (or intending to become pregnant within 2 years) or lactating females;
  • Concomitant participation in interventional clinical trials of other clinical trial drugs, except for questionnaire surveys or observational studies;
  • Any situation in which the programme is not in compliance;
  • Other conditions that in the opinion of the investigator are not suitable for participation in this study.

Quoted from ClinicalTrials.gov, NCT06436677, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06436677, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06436677